改良的阿柏西普治疗并延长方案治疗视网膜分支静脉阻塞所致黄斑水肿的疗效：1年前瞻性研究

Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study.

作者信息

Arai Yusuke, Takahashi Hidenori, Inoda Satoru, Sakamoto Shinichi, Tan Xue, Inoue Yuji, Tominaga Satoko, Kawashima Hidetoshi, Yanagi Yasuo

机构信息

Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.

Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Tokyo 162-8543, Japan.

出版信息

J Clin Med. 2020 Jul 23;9(8):2360. doi: 10.3390/jcm9082360.

PURPOSE

To assess the efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO).

METHODS

This prospective multicentre intervention study evaluated 50 eyes of 50 patients enrolled from October 2016 to September 2017. The patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for a total of 12 months. The main outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months.

RESULTS

The baseline BCVA and CST were 0.33 (0.27) and 488 (171) µm (mean (standard deviation)), respectively. The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110) µm; both < 0.0001, paired -test). The mean number of clinic visits and IVA injections was 6.71 (1.41) and 4.26 (0.71), respectively. The time to first recurrence from the first injection was most frequently 3 months.

CONCLUSION

The mTAE regimen of IVA injections for ME due to BRVO effectively improved BCVA and reduced CST, and thus might be an effective therapy to reduce the number of injections and visits.

目的

评估阿柏西普改良治疗并延长（mTAE）方案治疗视网膜分支静脉阻塞（BRVO）所致黄斑水肿（ME）的疗效和安全性。

方法

这项前瞻性多中心干预研究评估了2016年10月至2017年9月纳入的50例患者的50只眼。患者接受玻璃体内注射阿柏西普（IVA），采用mTAE方案，共治疗12个月。主要观察指标为12个月时的最佳矫正视力（BCVA）和中心子野厚度（CST）。

结果

基线时BCVA和CST分别为0.33（0.27）和488（171）µm（平均值（标准差））。12个月时BCVA和CST显著改善（分别为0.067（0.19）LogMAR和295（110）µm；均<0.0001，配对检验）。平均门诊就诊次数和IVA注射次数分别为6.71（1.41）和4.26（0.71）。从首次注射到首次复发的时间最常见为3个月。